Cannabis Rescheduling: How U.S. Research Will Finally Move Forward

For decades, cannabis research in the United States has existed in a paradox. Millions of patients use cannabis legally under state programs, clinicians observe real-world outcomes every day, and yet federally sanctioned research has lagged far behind public use. The recent executive action by President Trump directing the federal government to move cannabis out of Schedule I represents a historic shift, because the path forward is now formally defined.

While cannabis has not yet been fully rescheduled to Schedule III, as it’s awaiting final execution of the order, the federal government has clearly acknowledged that it does not meet the criteria for Schedule I, which requires no accepted medical use and a high potential for abuse. That acknowledgment alone reshapes the research landscape. The scientific barriers that once discouraged universities, hospitals, and federal agencies from engaging in cannabis research are beginning to loosen, even before the final rule is published.

Understanding what happens next requires patience and realism. Scientific research moves far more slowly than policy announcements, and meaningful medical insights emerge over years, not months.

Let’s explore the next steps for cannabis research in the United States.

From Executive Action to Scientific Access: Laying the Groundwork

The executive directive instructing federal agencies to complete the rescheduling process orders the Department of Justice, the DEA, and the Department of Health and Human Services to finalize a rulemaking process that has already undergone scientific review.

Crucially, that scientific review, conducted by HHS and the FDA, concluded that cannabis has accepted medical use and a lower abuse potential than Schedule I substances. This conclusion is binding on the DEA from a scientific standpoint. What remains is administrative procedure: public notice, comment, potential hearings, and the issuance of a final rule.

For researchers, this distinction matters. While full Schedule III status will significantly reduce regulatory friction, the signal has already been sent. Federal agencies, institutional review boards, and grant-making bodies now have political and scientific cover to plan future cannabis studies without fearing that the foundation will collapse beneath them.

Why Cannabis Research Has Historically Taken So Long

To understand future timelines, it’s important to understand why cannabis research has moved so slowly in the past.

Schedule I status imposed extraordinary burdens on researchers. Investigators needed special DEA licenses, faced limited access to research-grade cannabis, navigated redundant approval layers, and often encountered institutional resistance due to legal risk. Even well-funded studies could take years just to receive authorization, let alone produce results.

Rescheduling does not eliminate scientific rigor, nor should it. But what it does eliminate is unnecessary obstruction. Researchers studying Schedule III substances like ketamine or anabolic steroids still follow strict protocols, but they are not treated as if they are handling substances with no legitimate medical value.

This shift alone is expected to compress early-stage research timelines, especially for observational studies and small clinical trials.

What Research Timelines Will Look Like After Rescheduling

Swipe to scroll →

Even under ideal conditions, cannabis research will unfold in phases.

In the first one to three years after rescheduling is finalized, the most visible expansion will occur in preclinical and early clinical research. Universities and medical centers that have been hesitant to engage will begin launching pilot studies, dose-finding trials, and retrospective analyses using existing patient data from state-legal programs.

During this phase, researchers will focus on safety profiles, pharmacology, and mechanism of action. These studies rarely make headlines, but they are foundational. Understanding how cannabinoids interact with the endocannabinoid system, immune signaling, neurotransmitters, and metabolic pathways is essential before large-scale trials can be responsibly designed.

Between three and seven years out, the field is likely to see a surge in Phase II and Phase III clinical trials, particularly for conditions where there is already strong observational evidence of benefit. These trials take time because they are expensive, heavily regulated, and designed to answer narrow, specific questions. This is the phase where cannabis-derived therapies begin to resemble conventional medicine in structure.

Truly definitive conclusions, as in the kind that reshape clinical guidelines, often take a decade or more. This is not unique to cannabis. It is the normal pace of medical science.

Future of Cancer Research: Beyond Symptom Management

Cannabis research in oncology is often misunderstood. While cannabinoids are not currently positioned as cancer cures, they are of significant interest in both symptom management and tumor biology.

In the near term, research will continue to focus on chemotherapy-induced nausea and vomiting, appetite stimulation, pain, and sleep disturbances. These are areas where cannabis already shows real-world efficacy and where randomized controlled trials can be ethically and practically conducted.

Longer-term cancer research explores more complex questions, including whether cannabinoids influence tumor growth, angiogenesis, apoptosis, or immune modulation. These studies begin in cell cultures and animal models and may take many years before human trials are appropriate. Rescheduling makes this work easier to fund and conduct, but it does not shortcut the scientific method.

Chronic Pain: A Public Health Priority

Chronic pain is one of the most urgent areas of cannabis research, particularly in the context of the opioid crisis. Millions of Americans live with pain that is poorly managed by existing pharmaceuticals or accompanied by serious side effects.

Early research will likely focus on comparative effectiveness and explore how cannabis performs relative to opioids, NSAIDs, and nerve-targeting medications. Researchers will examine not only pain reduction, but functional outcomes, quality of life, dependency risk, and long-term safety.

Because chronic pain is diverse meaningful insights will require condition-specific studies. This takes time, but rescheduling removes a major bottleneck that has prevented large health systems from participating at scale.

PTSD and Mental Health: Careful, Controlled Progress

Post-traumatic stress disorder is another area of intense interest, especially among veterans. Observational data suggest cannabis may help with sleep, hyperarousal, and anxiety, but mental health research demands exceptional caution.

Expect early studies to focus on symptom clusters rather than broad diagnostic claims. Researchers will also pay close attention to dosing, cannabinoid ratios, and potential risks, particularly for individuals with comorbid anxiety or psychotic disorders.

Because mental health outcomes are complex and subjective, this research will likely unfold more slowly than pain or nausea studies. However, rescheduling makes it far easier for federally affiliated researchers to engage without institutional risk.

Emerging Medical Conditions Under Cannabis Research

Beyond the headline conditions, researchers are actively exploring cannabis in epilepsy, multiple sclerosis, inflammatory bowel disease, sleep disorders, neurodegenerative diseases, and more. Each of these will follow the same time-consuming, deliberate arc from hypothesis to evidence.

What Cannabis Rescheduling Means for Medical Science

Rescheduling cannabis does not instantly legitimize every claim made about it, nor does it need to. What it does is return cannabis to the realm of normal scientific inquiry, where claims can be tested, refined, and sometimes disproven.

The most important shift is cultural as much as regulatory. Cannabis research will no longer be treated as fringe or risky within academic medicine.

The Bottom Line

The path forward is now clear, even if the destination is still years away. Cannabis research will expand steadily, responsibly, and methodically. Early insights will emerge within a few years, while transformative conclusions will take longer.

This is not a delay; it is how science works when it is finally allowed to.